GSA Capital Partners LLP lowered its stake in shares of Retrophin Inc (NASDAQ:RTRX) by 18.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 11,700 shares of the biopharmaceutical company’s stock after selling 2,700 shares during the period. GSA Capital Partners LLP’s holdings in Retrophin were worth $291,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. SG Americas Securities LLC increased its stake in shares of Retrophin by 1.8% in the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 146 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Retrophin by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 355 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Retrophin in the 3rd quarter valued at about $203,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Retrophin in the 3rd quarter valued at about $212,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Retrophin in the 3rd quarter valued at about $249,000.
Retrophin Inc (NASDAQ RTRX) opened at $23.29 on Wednesday. The company has a quick ratio of 3.83, a current ratio of 3.88 and a debt-to-equity ratio of 0.15. Retrophin Inc has a 52 week low of $15.55 and a 52 week high of $26.44. The firm has a market capitalization of $894.00, a PE ratio of -17.64 and a beta of 1.45.
Several equities analysts recently weighed in on RTRX shares. BMO Capital Markets restated a “buy” rating and issued a $44.00 price target on shares of Retrophin in a research note on Friday, October 6th. Zacks Investment Research lowered Retrophin from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 14th. ValuEngine lowered Retrophin from a “hold” rating to a “sell” rating in a research note on Monday, November 20th. Finally, BidaskClub lowered Retrophin from a “buy” rating to a “hold” rating in a research note on Saturday, December 30th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Retrophin currently has a consensus rating of “Hold” and an average price target of $44.00.
WARNING: This article was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.themarketsdaily.com/2018/01/10/gsa-capital-partners-llp-sells-2700-shares-of-retrophin-inc-rtrx.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.